Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma.

Abstract

BACKGROUND The goal of induction in younger MM patients is to improve performance status and symptoms, enabling autologous stem cell transplantation (ASCT). It is unclear whether intensification of induction regimens improves post transplant outcomes. PATIENTS AND METHODS We studied 178 MM patients who received conservative steroid-based induction therapy without novel agents before ASCT between 2000 and 2006 and correlated induction parameters (rapidity of response, need for salvage induction therapy, depth of response) with transplant outcomes. RESULTS Fifty-three percent of patients achieved at least a partial response by cycle 2 (early responders). Rapidity of induction response did not translate into a significant difference in post transplant progression-free survival (PFS) (20.7 vs. 20.0 months; P = .24) or overall survival (OS) (64.4 vs. 51.3 months, respectively; P = .13). In 41 patients (23%) the first induction regimen failed, but they responded to salvage and proceeded to ASCT. They had inferior PFS (15.6 vs. 21.8 months; P = .008) and OS (43.5 vs. 69.4 months; P = .0004) post transplant compared with those requiring 1 regimen. CONCLUSION Rapid response to induction therapy does not correlate with PFS or OS post ASCT when using a conservative steroid-based induction regimen. Patients in whom this initial induction fails have worse post transplant outcomes, thus the upfront use of intensive therapies with novel agents should be considered.

DOI: 10.1016/j.clml.2012.08.008

Statistics

050010001500201520162017
Citations per Year

176 Citations

Semantic Scholar estimates that this publication has 176 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Prica2013RapidityAQ, title={Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma.}, author={Anca A Prica and Young Trieu and Wei Xu and Donna E. Reece and Suzanne Trudel and Vishal Kukreti and Christine I Chen}, journal={Clinical lymphoma, myeloma & leukemia}, year={2013}, volume={13 1}, pages={25-31} }